Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level

21 Jan 2024

Abstract excerpt

Background: Although highly efficacious, immune checkpoint inhibitors induce a multitude of immune-related adverse events including lichenoid skin reactions (irLP) that are often therapy-resistant. Objectives: To compare the clinical, histological, and transcriptional features of irLP with spontaneous lichen planus (LP). Methods: Clinical and histological presentations of irLP and LP, as well as the gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Oral Health Pathology and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38882039
DOI: 10.1016/j.jdin.2023.11.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelPMID 38882039Read ↗

IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planusSemantic proximity Read ↗

Use of JAK Inhibitors in Lichen Planus: An UpdateSemantic proximity Read ↗

Comprehensive Insight into Lichen Planus ImmunopathogenesisSemantic proximity Read ↗

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen PlanopilarisSemantic proximity Read ↗

Oral Baricitinib in the Treatment of Cutaneous Lichen PlanusSemantic proximity Read ↗

Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cellsSemantic proximity Read ↗

Oral lichen planus: a novel staging and algorithmic approach and all that is essential to knowSemantic proximity Read ↗

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity Read ↗

Single-cell sequencing combined with spatial transcriptomics reveals the characteristics of follicle-targeted inflammation patterns in primary cicatricial alopeciaSemantic proximity Read ↗

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity Read ↗

Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic ImmunofluorescenceSemantic proximity Read ↗

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.